Thyrocare - Covid-19 Tests Contribution Reduces Sharply In Q3: ICICI Securities 

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

Thyrocare Technologies Ltd. reported slower recovery in non-Covid-19 business in Q3 FY21 and contribution from Covid-19 has also declined considerably.

Revenue grew 30.7% YoY to Rs 1.4 billion (our estimate Rs 1.5 billion). Ebitda margin dropped 550 basis points YoY (down 450 basis points QoQ) to 35.9% (our estimate 39.3%).

The company conducted 0.45 million Covid-19 tests which contributed approximately 24% to total sales in Q3 FY21.

Regular pathology business witnessed a volume decline of 5.6% in the number of samples but improved sequentially with easing of lockdown.

The performance had been below estimates, though base business is gradually recovering.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.